Stephen Willey, an analyst from Stifel Nicolaus, maintained the Buy rating on Abeona Therapeutics. The associated price target is $19.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Stephen Willey has given his Buy rating due to a combination of factors that bolster confidence in Abeona Therapeutics’ future performance. Despite a temporary setback in the commercial launch timeline due to a sterility assay issue, the company has shown resilience by optimizing their processes and resuming patient biopsy collections. This proactive approach is expected to support the resumption of patient treatments in the fourth quarter of 2025, aligning with their FY26 launch goals.
Moreover, there is a growing demand for Abeona’s Zevaskyn product, with management identifying numerous eligible patients and receiving product order forms. The company’s efforts in securing broad insurance coverage, including a permanent J-code, further strengthen the market acceptance of Zevaskyn. These developments, coupled with a strong cash position, are expected to drive profitability in early FY26, presenting an attractive risk/reward scenario for investors.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABEO in relation to earlier this year.